Health-care powerhouse Johnson & Johnson (JNJ 1.49%) has thrived for years on its diversity and safety, but the company's pharmaceuticals division has emerged as its best attraction for growth investors. Indeed, J&J's drug sales paved the way for another quarter of expectations-beating earnings, as the company released its second quarter data this week.
Star blockbuster immunology drug Remicade has long held down strong sales for J&J, and new upstarts such as diabetes-fighting drug Invokana are on their way to laying the groundwork for the company's future pharmaceutical success. Will this optimism be enough to keep this strong stock flying high in the future? Motley Fool contributor Dan Carroll tells you what you need to know about the performance at J&J's pharmaceutical division -- and what it means for your portfolio.
